Table 1. Antiarrhythmic agents for pharmacological cardioversion^*.

Agent	Primary dose regimen	Subsequent dose regimen	Notes
Amiodarone	5 mg/kg BW IV over 1 h	approx. 50 mg/h	Potential acute adverse events: phlebitis. hypotension
Flecainide	2mg/kg BW IV over 10 min or 200–300 mg orally		Not in patients with marked structural heart disease. risk of QRS interval widening. QT prolongation. and atrial flutter with fast conduction
Propafenone	2 mg/kg BW IV over 10 min or 450–600 mg orally		Not in patients with marked structural heart disease. risk of QRS interval widening and atrial flutter with fast conduction
Vernakalant	3 mg/kg BW IV over 10 min		Limited approval

^*modified according to (4)